Actively Recruiting
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
Led by University Hospital, Strasbourg, France · Updated on 2025-04-02
130
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.
CONDITIONS
Official Title
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (≥18 years old)
- Operated on at the HUS between January 1, 2010 and December 31, 2022
- Having undergone primary or interval cytoreductive surgery
- Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin
You will not qualify if you...
- Patient who has opposed the reuse of her data for scientific research purposes
- Other histological types of ovarian cancer
- Disease stages FIGO I, II, IIIA and IIIC
- Closure surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France
Strasbourg, France
Actively Recruiting
Research Team
L
Lise LECOINTRE, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here